Webcast Optimizing Next Generation Sequencing (NGS)-Based Test Validation

Optimizing Next Generation Sequencing (NGS)-Based Test Validation

 · America/Chicago

About This Webcast

Join us for an insightful session on laboratory-developed next-generation sequencing (NGS) tests. Based on the CAP's Molecular Pathology and All Common Checklists, we'll delve into the key elements required to launch NGS tests in both somatic and germline applications. This webinar will cover analytical performance metrics, including accuracy, specificity, reportable range, and reference intervals. Additionally, we'll explore the wet bench and bioinformatics aspects of validation, equipping laboratories with the knowledge to excel in NGS testing. At the conclusion of the presentation, our speaker will answer questions submitted during registration. Objectives: Understand the validation process for NGS-based LDTs. Review the CAP Molecular Oncology and All Common checklist items as they pertain to NGS testing. Identify crucial components for successful NGS-based test validation. Discover valuable resources for participating laboratories. This is one of two identical sessions to serve global audiences. Click here to see a start time conversion for this session. Our second webinar session takes place 12 hours earlier. Click here to register for that session instead.

Speakers

Yassmine Akkari, PhD

Yassmine Akkari, PhD

Senior Director , Institute for Genomic Medicine at Nationwide Children’s Hospital

Dr. Yassmine Akkari, Senior Director at the Institute for Genomic Medicine, Nationwide Children’s Hospital, and Professor of Pathology at Ohio State University College of Medicine, holds triple certification in Clinical Cytogenetics, Clinical Molecular Genetics, and PhD Medical Genetics from the American Board of Medical Genetics and Genomics. With a background in Biology from the American University of Beirut, she earned her PhD in Molecular Genetics at The Ohio State University. Dr. Akkari's expertise spans various roles, including Scientific Director of Cytogenetics and Molecular Pathology at Legacy Health in Portland, Oregon. Her contributions include validating cytogenetic testing, pan-cancer solid tumor next-generation sequencing panels, and infectious disease testing. She directed clinical genetics operations, provided genetic counseling, and achieved ISO 15189 accreditation for laboratories. Actively involved in professional organizations, Dr. Akkari has served as President of the Cancer Genomics Consortium and held leadership roles in CAP/ACMG, AMP, WHO Blue Books, and ACMG committees. She focuses on genomics in disease diagnostics and therapy, particularly in prenatal and postnatal genetics, pediatric hematologic disease, CNS tumors, and genetic predisposition syndromes.